🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — March 23, 2026

Across 50 US SEC filings for FY2025 (ended Dec 31, 2025), sentiment is predominantly mixed (28/50), with neutral ABS trusts (12/50) and negative outliers in consumer/hospitality sectors; revenue trends show sharp declines in consumer goods (avg -30% YoY for Aterian, Solo Brands) offset by growth in mining/biotech (e.g., Idaho Strategic +64.6% YoY, Arbutus +128% YoY). Net losses widened in 18 companies (avg +45% YoY in biotechs like Cabaletta, Surrozen), but narrowed in 12 (e.g., Xilio -40%, Sutro -16%); cash positions improved in 15 firms via financing/IPOs, but burned in biotech heavy-hitters. SPACs (Cartesian, SilverBox, Bold Eagle, TGE) reported strong trust interest income (+300-400% YoY) amid negative equity, signaling de-SPAC catalysts. Capital allocation leaned toward debt reduction (Core Labs -13% net debt, Ultralife -12%) over dividends/buybacks; insider activity limited to 10b5-1 selling plans (Avalo, Pyxis) indicating caution. Portfolio-level: Biotech R&D surges (+30-180% YoY) drive losses but fuel pipelines; consumer margin resilience amid sales drops offers turnaround potential; ABS compliance uniform/neutral implies stable securitizations.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 23, 2026

Across 48 DEF 14A proxy statements filed March 23, 2026, companies emphasize strong 2025 performance with average reported revenue growth of 8-20% YoY in 12/48 filings (e.g., AbbVie +8.5% to $61.2B, Gallagher +20.7% to $13.7B), robust capital returns including dividend increases (AbbVie to $1.73/share, Kimberly-Clark 54th consecutive year), and buybacks (RLJ $28.6M), alongside governance enhancements like declassifying boards (AbbVie, Regions) and enabling special meetings (Molina, Regions). Key trends include outperformance vs. benchmarks (Progressive 1.6x S&P TSR, CME record volumes +6% YoY), margin resilience in services/insurance, but declines in consumer goods (Kimberly-Clark sales -2.1% YoY) and hospitality (RLJ constrained RevPAR). Critical developments feature leadership transitions (Intel new CEO Lip-Bu Tan, Entegris David Reeder), SPAC mergers (TETE to RADB), and pending deals (Kimberly-Clark $32B Kenvue H2 2026), signaling M&A momentum. Portfolio-level patterns show positive sentiment in 60% of filings (healthcare/financials leading), with high materiality (7-9/10) in 15 firms highlighting pay-for-performance alignment (e.g., Enpro 130.5% payouts). Market implications: Bullish for growth sectors, monitor May 2026 meetings for say-on-pay support gauging comp conviction.

48 high priority 48 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 23, 2026

Across 46 filings in the USA Corporate Distress & Bankruptcy stream (32 new), the dominant theme is aggressive liquidity bolstering via 18+ new/expanded credit facilities, 12 equity/debt raises, and 8 refinancings extending maturities (avg ~3yrs) and cutting rates (e.g., California Resources 8.25% to 7%), signaling stabilization rather than deepening distress. Period-over-period highlights include Sutro Biopharma's FY2025 revenue +65% YoY to $102.5M, R&D -34% to $166.4M, net loss improved -16% to $191.1M; RenovoRx $900k rev in 9M2025 from commercialization. Insider conviction strong in RenovoRx (mgmt/board participation), Empery Digital ($200M buybacks at $5.92 avg). Critical developments: Volato NYSE delisting risk (equity < $2M/4M), MSP Recovery liquidity crunch ($75k advance + CRO). Portfolio trends: Positive sentiment 60% (28/46), financing materiality avg 8/10; bearish outliers in microcaps. Implications: Short-term survival plays dominant, alpha in refi beneficiaries and biotech catalysts, monitor delistings for shorts.

46 high priority 46 total filings
· daily

US SEC Trading Suspension Halt Orders — March 23, 2026

Across the single filing in the USA Trading Suspensions stream, Volato Group, Inc. (SOAR) faces severe NYSE American delisting risk due to stockholders’ equity falling below $2.0M (losses in two of three recent fiscal years) and $4.0M (losses in three of four recent fiscal years), signaling prolonged financial distress with no provided YoY/QoQ recovery trends. Negative sentiment dominates with 9/10 materiality, highlighting non-compliance under Sections 1003(a)(i) and 1003(a)(ii) of the Company Guide. No immediate trading suspension impacts Class A Common Stock (SOAR) on NYSE American, but warrants (SOARW) already trade on OTC Markets, foreshadowing potential further liquidity erosion. Absent enriched data on insider activity shows no management buying conviction, while forward-looking compliance deadlines (plan by April 16, 2026; regain standards by December 17, 2026) create a high-stakes catalyst calendar. Capital allocation details unavailable, but sustained losses imply strained shareholder returns with no dividends or buybacks noted. Portfolio-level theme: isolated small-cap aviation player exemplifies regulatory vulnerability amid equity deficits, urging immediate position reviews.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 23, 2026

Across 38 US SEC filings dated March 23, 2026, focused on boardroom changes, a dominant theme emerges of strategic leadership successions and transitions, with 12 positive sentiment cases (e.g., orderly CEO handovers in 4 Gladstone entities), 15 neutral director retirements/resignations, and 5 negative/mixed signals amid operational challenges like missed milestones. No broad YoY revenue growth trends reported, but period comparisons highlight BioAtla's 2025 bonus misses (0% payout) vs retention incentives for 2026 milestones, contrasting with reaffirmed FY26 outlooks (Cardinal Health). Insider-like conviction shines in internal promotions (e.g., Oil States CFO to CEO, Crawford interim to permanent) signaling stability, while 7 CEO/CFO departures raise continuity risks. Portfolio-level pattern: Biotech/healthcare (8 filings) shows 50% turnover rate with mixed milestones; finance/REITs (10 filings) emphasize governance separations (Chairman/CEO split). Forward catalysts cluster Q2 2026 (earnings, AGMs, milestones), implying near-term volatility but alpha in smooth transitions. Capital allocation leans retention bonuses/RSUs over buybacks, with no dividend/split changes noted.

38 high priority 38 total filings
· daily

US Merger & Acquisition SEC Filings — March 23, 2026

The 10 filings reveal heightened US M&A and takeover activity dominated by SPACs (7/10 filings), with extensions, approvals, and high redemptions signaling persistent deal momentum amid liquidity pressures; actual sector M&A includes mining consolidation (Coeur-New Gold boosting 2026 gold production guidance 80% YoY from 419k oz to 680-815k oz), reinsurance divestiture (FG Nexus), crowdfunding expansion (StartEngine-Vinovest adding $140-150M AUM), and governance tweaks post-acquisition (Exact Sciences). Period-over-period trends show SPAC trust deposits for extensions (YHN $150k) contrasting low balances (TETE $142k signaling redemptions), while Coeur's reserves integration extends mine life to 2032-2035 with strong FCF projections. Capital allocation shines in Coeur's $750M buyback and inaugural $0.02/share dividend vs prior $400M facility upgrade to $1B revolver. Overarching themes: SPAC resilience via extensions/name changes (Goldenstone to Chi Special) but delisting risks (Bayview); positive sentiment in 6/10 filings drives alpha in mining/alts, mixed in SPACs due to redemptions (Crane 19.4M shares/$201M). Portfolio implication: Favor completed M&A with guidance upside over pre-merger SPACs; monitor March 26-31 catalysts for volatility.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 23, 2026

Across 50 overnight SEC filings, dominant themes include mixed 2025 full-year results in 10-Ks with revenue growth in select miners/banks (e.g., Idaho Strategic +64.6% YoY, Finwise +26% net income) offset by declines in consumer/hospitality (Aterian -30.4%, Ashford -5.8% revenue), alongside M&A progress (Thermon/CECO synergies >$40M, Sealed Air regulatory clearances), debt refinancings (Nortech $15M revolver to 2029, Ormat $750M notes), and biotech catalysts (Apogee 52-week data supporting Phase 3 in 2H2026). Portfolio-level trends show 7/15 10-Ks with revenue growth averaging +28% YoY but 5 with net losses widening (avg +45%), margin compression in 4/10 (avg -200bps), and improving balance sheets in 6/10 via debt reduction/cash builds. Positive capital allocation signals like News Corp $1B buybacks and Ormat stock repurchases contrast cyber risks (Heritage incident) and delisting threats (Volato). Critical developments: Faraday Future SEC clearance removes overhang; Apogee AD data positions for $50B market. Implications favor energy/mining longs, M&A arbitrage, caution hospitality/consumer shorts amid pre-market positioning.

36 high priority 14 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 22, 2026

Tayo Rolls Limited (Stock Code: 504961) exemplifies a high-priority insolvency event with prolonged Corporate Insolvency Resolution Process (CIRP) ongoing since October 30, 2019, now exceeding 6 years without full resolution. NCLT approved JBVNL's acquisition resolution plan on December 17, 2024, but implementation remains stayed by NCLAT, leading to a deadlock in quarterly and annual statutory compliances for periods ended March 31, 2025. The erstwhile Compliance Officer, Harpreet Kaur Bhamra, cites inaction by Resolution Professional M. Anish Agarwal and Successful Resolution Applicant (JBVNL), compounded by inoperative company email and website. Negative sentiment prevails with 9/10 materiality, signaling severe governance and operational paralysis. No period-over-period financial comparisons, ratios, or operational metrics available due to insolvency stasis, highlighting zero growth or margin trends amid stagnation. Portfolio-level implication: single distressed manufacturing asset underscores risks in unresolved bankruptcies, advising avoidance for long-only investors. Critical market event flags potential delisting or further value erosion for shareholders.

1 high priority 1 total filings
· daily

Global High-Priority Regulatory Events — March 21, 2026

Across the 7 filings in the Global High Priority Market Events stream, dominant themes include a full leadership overhaul at Classic Filaments Limited following a successful Open Offer and change in control (2 filings), ongoing Corporate Insolvency Resolution Processes (CIRP) for Remedium Lifecare Limited and Radhagobind Commercial Limited signaling acute distress in healthcare and commercial sectors, minor regulatory resolutions for Burnpur Cement (penalty reversal) and Gujarat Kidney And Superspeciality Limited (fines paid), and an upcoming RBI State Government Securities auction. No explicit period-over-period financial trends (YoY/QoQ revenue, margins) are available across filings, but event-driven metrics highlight debt defaults (e.g., ₹7.47 Cr at Remedium) and penalty reversals/fines (₹1.56L reversed vs. ₹6.60L paid). Critical developments point to takeover completion as a potential turnaround catalyst amid pervasive insolvency risks, with mixed sentiment in control change and uniformly negative tones in insolvencies (materiality 10/10). Portfolio-level patterns reveal heightened credit and governance risks in Indian small-caps, particularly healthcare, warranting avoidance of insolvent names while monitoring post-takeover value unlocks and fixed-income auctions for relative safety.

7 high priority 7 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 20, 2026

Across 46 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly interpreted to include adjacent defensive sectors like pharma and logistics), dominant themes include robust revenue growth in 6/12 companies reporting financials (avg +100% YoY, e.g., Belpointe PREP +244%, Yellowstone +52%, Cellectis +61.7%), offset by mixed profitability with 4/12 showing widening net losses (avg +60% YoY deterioration). SPAC and M&A activity peaks with Pelican-Greenland merger approval despite 63% redemptions, Constellation-Calpine completion, and pending KORE $9.25/share cash deal, signaling consolidation. Proxy statements (12/46) highlight 2025 successes like Eli Lilly's $65.2B revenue/40% TSR outperformance and Penske's $31.8B revenue/$182M buybacks, fostering bullish sentiment amid AGMs in Apr-May 2026. Risks emerge from Nasdaq bid price deficiencies (Faraday Future, TELA Bio), repeated insider debt extensions (Perfect Moment), and leadership churn (CleanCore CEO resignation). Capital allocation leans shareholder-friendly with dividends (Helios $0.12/share, Apr27 record) and buybacks, but high debt growth (Belpointe +47% YoY) flags leverage concerns. Portfolio implication: Selective opportunities in outperforming revenue growers like Eli Lilly/Penske, monitor SPAC closes for volatility.

25 high priority 21 medium 46 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 20, 2026

Across 50 SEC filings from diverse sectors (despite Industrials focus, including media, pharma, banks, retail, and select industrials like GPC and GNK), key themes include mixed financial performance with revenue growth in 6/15 detailed reporters (avg +6% YoY, e.g., Dollar General +5.2%, QIAGEN +6%) offset by widening losses in 8/15 (avg +40% YoY, e.g., Urban One net loss +39%, Milestone Pharma +52%). M&A activity surges with accretive deals like Prestige's $1.045B Breathe Right acquisition (11x EBITDA, immediately accretive to EPS/FCF) and bank mergers (Stock Yards, Independent Bank), signaling consolidation. Capital allocation leans toward equity raises/financings (Benitec +92% cash, Palisade +$134M) amid cash burn concerns. Insider/leadership signals neutral with resignations (GPC CIO, FIS CPO) but positive appointments (Global Indemnity COO). Forward catalysts cluster in H1 2026: deal closes (Prestige H1 FY27), earnings (Civista Apr 22), AGMs (multiple Apr-May). Portfolio implication: Favor acquisitive consumer/health names over loss-making media/pharma; monitor bank NIM compression (Chain Bridge -7 bps).

29 high priority 21 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 20, 2026

Filings from the S&P 500 Energy stream reveal a mix of capital raising initiatives and modest operational updates in energy-adjacent sectors like oil tankers, with Okeanis Eco Tankers reporting a slight 0.4% YoY revenue decline to $391.5M for 2025 despite 1.3% TCE growth to $265.4M driven by 1.4% higher operating days at 5,025. Papa Medical's S-1/A signals IPO readiness with $15M gross proceeds targeted at $4/share, underscoring funding for hemp-derived products potentially tied to energy-alternative markets. Bioxytran completed a $1.2M private placement at $0.055/share, issuing 21M shares and warrants, reflecting positive sentiment amid working capital needs. AParadise Acquisition Corp.'s 425 filing promotes a SPAC merger with Enhanced Games, highlighting a May 24, 2026 catalyst event amid regulatory shift hopes for peptides. Portfolio-level trends show 1/4 filings with YoY revenue contraction (Okeanis -0.4%), but positive capital inflows averaging ~$10M+ per issuance; mixed sentiments dominate (50% mixed), with new issuances bullish. Key implication: Energy services face flat TCE rates (-0.1% YoY at $52,823), pressuring margins, while SPACs and placements offer entry points ahead of catalysts.

3 high priority 1 medium 4 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 20, 2026

Across 50 SEC filings from diverse sectors (despite Financials stream focus, data spans tech, health, retail, SPACs), mixed sentiment prevails in 70% of material filings (>5/10), with 12/20 10-Ks showing revenue growth averaging 72% YoY (e.g., Firefly +163%, Aeva +99%, Belpointe +244%) but net losses widening in 8/12 by avg 55% YoY due to op ex surges and impairments. Margin expansions noted in 5 cos (QIAGEN +1339bps gross, Latham +320bps, Dollar General +107bps), contrasting compression elsewhere; M&A/SPAC activity peaks with Embecta/Pelican deals closing soon, Prestige accretive acq. Capital allocation lean: News Corp $1B buyback ongoing, limited dividends/insider trades (no major buys/sells flagged). Proxy season ramps with 15+ AGMs Apr-May 2026 as catalysts; Financials-specific: Civista Q1 earnings Apr22, Metro Bank AI push/headcount +10%. Portfolio implication: Favor rev accelerators with margin inflection (Dollar General, Latham) over loss-makers; watch SPAC redemptions (Pelican 63%) for dilution risks.

34 high priority 16 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 20, 2026

Across 50 8-K filings from March 20, 2026, the dominant theme is widespread executive churn with 17 instances of resignations, appointments, or transitions (e.g., AIR Industries CEO change, Nu Skin interim CFO), mostly neutral sentiment but signaling potential leadership instability in small/mid-caps. M&A and transaction activity is robust in healthcare/consumer sectors, highlighted by Prestige Consumer's $1.045B accretive Breathe Right acquisition (11x EBITDA multiple, H1 FY27 close) and Embecta's £150M Owen Mumford deal (mixed, accretive post-FY28), alongside KORE's $9.25/share cash merger. Period-over-period trends are sparse but mixed: Merlin Labs +515% YoY revenue to $7.6M (2025 vs 2024) yet net losses +35% to $74.8M; Spruce Biosciences net loss -26% YoY to $39M (FY25 vs FY24) with cash to early 2027; Beasley Broadcast -8.7% revenue CAGR to $206.2M FY25E (vs FY23); Prestige historical +3.4% revenue CAGR FY20-25. Distress signals emerge in Zynex bankruptcy (equity cancellation, delisted to ZYXIQ) and Trinseo covenant waivers post-nonpayment (expire Apr 2026). Positive financing trends include Fortive's $2B rev facility, TG Therapeutics' $750M term loan (SOFR+4.75%), and multiple amendments enhancing liquidity. Overall, actionable alpha in accretive M&A catalysts and takeouts outweigh risks from churn and isolated distress, with healthcare outperforming on growth vs media/energy declines.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 20, 2026

Across the 8 S&P 500 Technology stream filings, dominant themes include robust revenue growth in core software players like Snowflake (29% YoY to $4.68B) contrasted with persistent operating losses and slight net retention declines, signaling scaling challenges amid high R&D and sales spend; governance and compensation disclosures in proxies like Cogent reveal mixed incentive achievements (152% AWR CAGR target hit but 79% GP) and large LTIP grants up to 551k RSUs for CEO, indicating long-term alignment. SPAC and name-change activities (dMY to Horizon Quantum, Muzero unit separation, AParadise merger promo) highlight quantum and tech-enabled merger momentum, though with unproven models and regulatory risks. Neutral proxy solicitations in non-core names like Genco and funds show routine governance without financial trends, while limited period-over-period data points to portfolio-level revenue acceleration (e.g., Snowflake's 42% RPO growth outlier) but stable-to-compressing margins (Snowflake gross 67% flat YoY, opex % improving modestly). Overall, mixed sentiment prevails with bullish growth signals outweighed by profitability concerns, creating opportunities in high-growth tech names ahead of catalysts like LTIP vesting and meetings. Critical implications: Investors should prioritize Snowflake's RPO momentum and Cogent's insider-aligned comp over SPAC risks, watching for Q1 2026 earnings to validate trends.

5 high priority 3 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 20, 2026

Across 12 NASDAQ-100 related filings from March 20, 2026, proxy season dominates with 5 DEF/DEFA14A filings signaling imminent annual meetings and governance focus, while financial disclosures reveal mixed period-over-period trends: Zegna's FY2025 revenue declined 1.5% YoY to €1,917M but profit surged 20.5% YoY to €109M on 90 bps gross margin expansion; IPM reported FY2025 revenue of $23.6M with net loss down 42% YoY and Q4 Adjusted EBITDA turning positive post-transformation. Positive highlights include Gilead's robust HIV/oncology pipeline with up to 7 launches by 2033 and bulevirtide potential in 2026, AITX's new AI security order, and IPM's accretive acquisition adding 17k customers. Critical risks emerge in Faraday Future's Nasdaq delisting notice for sub-$1 bid price, granting 180 days to September 16, 2026, compliance. Portfolio-level patterns show profitability resilience amid revenue softness in luxury/shipping, SPAC liquidity/m erger progress, and limited insider details but LTIP grants signaling long-term alignment in Cogent/Gilead. Actionable implications favor monitoring pharma catalysts and avoiding delisting risks, with capital allocation tilting toward acquisitions/RSUs over dividends.

6 high priority 6 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 20, 2026

Across the 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily blue-chip adjacent with diverse small/mid-caps), financial performance is mixed: 14/25 annual reports (10-K/20-F) show revenue growth averaging +35% YoY (outliers like Aeva +99%, Yellowstone +52%), but 11 report declines averaging -15% YoY (e.g., Urban One -16.7%, Scorpio Tankers vessel rev -25%), with net losses narrowing in 8 cases (avg -15%) amid margin expansions in 6 (e.g., QIAGEN +1330 bps to 62.2%). M&A activity surges with 4 deals (KORE $9.25/share cash merger, Kennedy-Wilson merger, Stock Yards/Field & Main 0.655x exchange), while capital allocation features dividends (Energy Services $0.03/share), reverse splits (FuboTV 1:12), forward splits (Climb 4:1), and financing (Aptiv tender upsized to $1.371B). Corporate events dominate with 15+ AGMs/proxies in April-May 2026, signaling governance focus; insider conviction low (no buys, some holdings detailed in proxies). Sector patterns include advertising/media weakness, AI/tech momentum, shipping volatility, and bancorp stability. Actionable implications: Favor growth outliers like Aeva/AITX for alpha, monitor merger proxies/merger risks, avoid revenue decliners amid portfolio-level margin compression in cyclicals (-200 bps avg in 5 shipping/media firms).

30 high priority 20 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 20, 2026

Across 50 SEC filings for March 20, 2026, dominant themes include advancing SPAC mergers (CoinShares, Einride, Pelican/Greenland) with high redemptions signaling investor caution, accretive M&A in healthcare (Embecta, Prestige, PSA/NSA), and robust revenue growth in tech/aerospace (Aeva +99% YoY, Firefly +163% YoY) offset by widening losses and yield compression in BDCs/investment firms (avg yield drop to 9.1% from 10.0%). Retail (Dollar General +5.2% YoY sales, +107 bps gross margin) and biotech (Cellectis +61.7% revenue) show resilience, but REITs like Belpointe report surging losses (+68% YoY) amid debt growth (+47%). Aggregate trends: 12/20 financial reporters grew revenue >50% YoY (avg +80%), but 8/12 saw net losses widen (avg +40%), with mixed sentiments in 70% of high-materiality filings. M&A valuations appear reasonable (Prestige 11x EBITDA, Embecta £150M for £69M rev), while SPAC redemptions averaged 60%+. Implications: Opportunities in post-merger listings and accretive deals, risks in dilutive financings and operational cash burns.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 20, 2026

Across the 50 filings in the S&P 500 Consumer Discretionary stream (with broader exposure via SPACs, M&A targets, and adjacents), overarching themes include robust revenue growth in high-flyers like Firefly Aerospace (+163% YoY), FiEE (+868% YoY), and Snowflake (+29% YoY), contrasted by margin pressures and widening losses in scaling firms (e.g., AutoZone op profit -1.2% YoY, Scorpio Tankers net income -49% YoY). Retail standouts like Dollar General showed resilient +5.2% sales growth and +107 bps gross margin expansion, while capital allocation leaned toward buybacks ($250M at First Industrial, AutoZone $742M) and dividends (Energy Services $0.03/share). M&A activity surged with UniFirst-Cintas deal (H2 2026 close) and NSA-Public Storage, signaling consolidation; insider moves were muted but resignations prevalent (e.g., FIS CTO, Lifeward director). Portfolio-level trends: 12/20 revenue reporters posted >20% YoY growth (avg +150%), but 8/15 profitability metrics declined (avg net income -15%), with mixed sentiment (22 mixed, 10 positive). Forward catalysts cluster in Apr-May AGMs; watch Nasdaq compliance risks in Lifeward/FFIE. Implications: Tactical buys in growth retail/tech, caution on overlevered cyclicals amid mixed guidance.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 20, 2026

Across 29 filings in the USA S&P 500 Healthcare stream (with broader cross-sector context), dominant themes include the onset of 2026 proxy season with 15+ annual meetings clustered April-May, robust period-over-period profitability gains in select names (e.g., Eli Lilly $65.2B revenue, Spruce Biosciences net loss improved 26% YoY to $39M, Heritage Financial net income +56% YoY), and healthcare-specific catalysts like Gilead's pipeline advancements (7 HIV launches by 2033, bulevirtide 2026), Eli Lilly's superior Zepbound data (20.2% weight loss vs Wegovy 13.7%), Exact Sciences/Abbott merger closing March 23, and Artelo Biosciences' compelling Phase 2a trial (6.38% weight gain vs placebo loss). Margin trends mixed: expansions in Zegna (+90 bps gross to 67.5%) and Ameriprise (+40 bps adjusted to 26.9%) offset by compressions elsewhere (Zegna op margin -130 bps to 7.3%, Spruce G&A +16% YoY). Capital returns strong in financials (Ameriprise $3.4B +20% YoY, News Corp $1B repurchase), biotech financing mixed (Cingulate dilution risk from $25M facility, Spruce $50M loan). Healthcare outliers show pipeline conviction (Gilead, Lilly, Artelo positive sentiment 8-9/10 materiality) amid Nasdaq compliance risks (Lifeward negative 9/10). Portfolio implication: overweight pharma/biotech on catalysts, monitor governance votes and M&A closes for near-term volatility.

13 high priority 16 medium 29 total filings